Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Rhea-AI Summary

Axonics, a medical technology firm, will present at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 12:30 p.m. ET. The live webcast and replay will be available on their investor relations website. Axonics specializes in innovative therapies for bladder and bowel dysfunction, including a rechargeable sacral neuromodulation system and a urethral bulking agent, Bulkamid®. These products offer significant symptom relief to millions affected by overactive bladder, fecal incontinence, and stress urinary incontinence across the U.S. and Europe.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.

Axonics is scheduled to present at 12:30 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website.

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that has developed and is commercializing novel products for patients with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid^®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005006/en/

FAQ

When is Axonics scheduled to present at the BofA Securities Virtual Healthcare Conference?

Axonics is scheduled to present on May 13, 2021, at 12:30 p.m. Eastern Time.

Where can I watch Axonics' presentation at the BofA Conference?

The presentation will be available via a live webcast and archived replay on Axonics' investor relations website.

What products does Axonics offer for bladder and bowel dysfunction?

Axonics offers a rechargeable sacral neuromodulation system and Bulkamid®, a urethral bulking agent for symptom relief.

How many people are affected by overactive bladder and fecal incontinence?

Approximately 87 million adults in the U.S. and Europe suffer from overactive bladder, and about 40 million suffer from fecal incontinence.

What is the significance of Axonics' products in terms of market reach?

Axonics' clinically proven products are available at numerous medical centers across the U.S. and are covered by reimbursement in most European countries.